Aurobindo Pharma Secures FTC Approval for Lannett Acquisition

Aurobindo Pharma USA Inc. receives US FTC approval to acquire Lannett Company LLC, expanding its US manufacturing and diversifying into high-value generics.

Aurobindo Pharma USA Inc. has secured key approval from the US Federal Trade Commission (FTC) for its acquisition of Lannett Company LLC. This clearance marks a significant step for Aurobindo’s strategic expansion in the highly competitive U.S. generics market.

The Deal Details

Aurobindo Pharma USA Inc. will acquire 100% of the membership interest in Lannett Company LLC from Lannett Seller Holdco, Inc.
The subsidiary had previously signed a definitive agreement for this transaction.

Strategic Implications

This transaction is set to bolster Aurobindo’s presence and capabilities in the United States. It aligns with the company’s objective to:

Expand its U.S. manufacturing footprint and enhance existing domestic capabilities.
Strengthen its ability to serve the U.S. generics space effectively.
Achieve strategic diversification into a specialized, high-value therapeutic category.